突出肝癌免疫治疗的新靶点

StephenW

突出肝癌免疫治疗的新靶点
萨曼莎·拉夫
, 亚历山大·香农
, 乔尔·D·比恩
& Timothy M. Pawlik
2022 年 9 月 21 日收到，2022 年 11 月 19 日接受，接受的作者版本在线发布：2022 年 11 月 20 日，在线发布：2022 年 11 月 23 日

    下载引文 https://doi.org/10.1080/17474124.2022.2150841 CrossMark Logo CrossMark

抽象的
介绍

肝脏免疫微环境的改变可以在癌症的发生和发展中发挥关键作用。由于其进化上保守的免疫耐受状态，这在肝脏中尤其如此。慢性炎症的存在可通过破坏肝脏免疫微环境促进肝细胞癌 (HCC) 的发生和发展。最近，免疫疗法atezolizumab（PD-L1抑制剂）与贝伐珠单抗（VEGF抑制剂）联合成为晚期HCC推荐的一线全身治疗。
涵盖的领域

鉴于免疫治疗指南的最新更新和新出现的数据，我们在此概述了目前可用于治疗 HCC 的和新型免疫治疗方法，包括免疫检查点抑制剂、过继细胞治疗和疫苗开发。本综述进行了广泛的文献检索，以调查评估当前免疫疗法和建立新靶点的基准工作、临床研究和临床试验。文献侧重于最新研究，包括正在进行的临床试验，以更好地评估该领域的障碍和未来方向。
专家意见

鉴于 HCC 肿瘤的异质性，结果的改善可能来自针对多种免疫机制。联合免疫疗法的持续研究和临床试验对于推动该领域的发展是必要的。

关键词：

    肝细胞癌免疫治疗检查点抑制剂过继细胞治疗肝癌

StephenW

Highlighting novel targets in immunotherapy for liver cancer
Samantha M. Ruff
, Alexander H. Shannon
, Joal D. Beane
& Timothy M. Pawlik
Received 21 Sep 2022, Accepted 19 Nov 2022, Accepted author version posted online: 20 Nov 2022, Published online: 23 Nov 2022

    Download citation https://doi.org/10.1080/17474124.2022.2150841 CrossMark Logo CrossMark

ABSTRACT
Introduction

Alterations to the hepatic immune microenvironment can play a key role in the development and progression of cancer. This is especially true in the liver due to its evolutionarily conserved immunotolerant state. The presence of chronic inflammation can facilitate the development and progression of hepatocellular carcinoma (HCC) by disrupting the hepatic immune microenvironment. Recently, the addition of the immunotherapy atezolizumab (PD-L1 inhibitor) with bevacizumab (VEGF inhibitor) became the recommended first-line systemic treatment for advanced HCC.
Areas covered

Given recent updates to the guidelines and emerging data on immunotherapy, we herein provide an overview of currently available and novel immunotherapy approaches for the treatment of HCC, including immune checkpoint inhibitors, adoptive cell therapy, and vaccine development. This review performed an extensive literature search to investigate benchwork, clinical research, and clinical trials that evaluate current immunotherapy and establish new targets. Literature was focused on the most up-to-date research and included ongoing clinical trials to better evaluate the obstacles and future direction of the field.
Expert opinion

Given the heterogeneity of HCC tumors, improvement in outcomes will likely come from targeting multiple immune mechanisms. Continued research and clinical trials of combination immunotherapies are necessary to move the field forward.

KEYWORDS:

    Hepatocellular carcinomaimmunotherapycheckpoint inhibitorsadoptive cell therapyliver cancer

挚友888888

昨天听上海中山介绍中听到，在中山医院靶向药起作用只有百分之10多点，免疫治疗只有个位数起作用。那么还有很多人不起作用怎么办？